HCV synergizes with body weight in the promotion of insulin resistance

Journal of Viral Hepatitis

Volumn 18, Issue 2, 2011, Pages 135-141

  Delgado Borrego, A ^a,b,c   Kamegaya, Y ^b   Jordan, S H ^b   Agrawal, S ^b   Valim, C ^a   Chung, R T ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes; HCV; hepatitis C; insulin resistance; synergy

Indexed keywords

COMPLEMENTARY DNA; CORE PROTEIN; GLUCOSE; ISOPHANE INSULIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BODY MASS INDEX; BODY WEIGHT; DISEASE MODELS, ANIMAL; HEPATITIS C; INSULIN RESISTANCE; MALE; MICE; MICE, TRANSGENIC;

EID: 78751555111     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01291.x     Document Type: Article

References (46)

1. Sene D, Limal N, Cacoub P,. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004; 19: 357-381.
2. Allison ME, Wreghitt T, Palmer CR, Alexander GJ,. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139.
3. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063.
4. Durand JM,. Extrahepatic manifestations of hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1402.
5. Fraser GM, Harman I, Meller N, Niv Y, Porath A,. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996; 32: 526-530.
6. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
7. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH,. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30-33.
8. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-1072.
9. Rudoni S, Petit JM, Bour JB, et al. HCV infection and diabetes mellitus: influence of the use of finger stick devices on nosocomial transmission. Diabetes Metab 1999; 25: 502-505.
10. Ozyilkan E, Erbas T, Simsek H, Telatar F, Kayhan B, Telatar H,. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994; 235: 283-284. (Pubitemid 24210837)
11. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003; 125: 1695-1704.
12. Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-710.
13. Baron AD,. Impaired glucose tolerance as a disease. Am J Cardiol 2001; 88: 16H-19H.
14. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999; 48: 989-994.
15. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042-1048.
16. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-744.
17. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-1751.
18. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP,. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597.
19. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G,. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
20. Mbow ML, Sarisky RT,. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol 2004; 22: 395-399.
21. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J,. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-217.
22. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N,. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
23. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
24. Colditz GA, Willett WC, Rotnitzky A, Manson JE,. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
25. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC,. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
26. Bray GA,. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589.
27. Jazet IM, Pijl H, Meinders AE,. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003; 61: 194-212.
28. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R,. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 2003; 228: 1111-1117.
29. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-419.
30. Schneider R, Golzman B, Turkot S, Kogan J, Oren S,. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330: 157-160.
31. Racette SB, Weiss EP, Hickner RC, Holloszy JO,. Modest weight loss improves insulin action in obese African Americans. Metabolism 2005; 54: 960-965.
32. Keeffe EB,. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 2005; 3: S102-S105.
33. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067.
34. Kamegaya Y, Hiasa Y, Zukerberg L, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 2005; 41: 660-667.
35. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL,. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736.
36. Monto A,. Hepatitis C and steatosis. Semin Gastrointest Dis 2002; 13: 40-46.
37. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.
38. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R,. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-842.
39. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-2494.
40. Kasprzak A, Zabel M, Biczysko W, et al. Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J Histochem Cytochem 2004; 52: 29-38.
41. Jia HY, Du J, Zhu SH, et al. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2002; 1: 378-382.
42. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
43. Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003; 18: 1358-1363.
44. Neuman MG, Benhamou JP, Martinot M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999; 32: 537-545.
45. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001; 34: 173-182.
46. Dumoulin FL, Wennrich U, Nischalke HD, et al. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. J Hum Virol 2001; 4: 195-199.